Qubigen CEO Jonathan Hall to Present at BIO 2025 in Boston
- David Brooks
- 7 days ago
- 3 min read
Qubigen is thrilled to announce that our CEO, Dr. Jonathan M. M. Hall, will be presenting at the 2025 BIO International Convention in Boston.
Date | June 18, 2025 |
Time | 1:45 PM – 2:00 PM |
Location | Boston Convention & Exhibition Center 415 Summer St, Boston, MA 02210, USA |
Session Topic | Dr. Hall will delve into Qubigen's patented Federated AI system for drug design, highlighting how this approach enables the development of superior molecules without compromising proprietary data. This method is instrumental in accelerating the development of new therapeutics in our pipeline that might be unattainable through traditional means. |
Speaker Profile |
About Dr. Jonathan Hall
Dr. Hall is a distinguished figure in the biotech industry, recognized as an MIT TechReview Innovator Under 35 (Asia-Pacific) and an InDaily 40 Under 40 Entrepreneur. He holds dual Ph.D.s in Particle Physics and Nanotechnology/BioPhotonics. Previously, he co-founded Life Whisperer, an AI-enhanced fertility platform that was globally acclaimed and acquired in 2024. Currently, as CEO of Qubigen, Dr. Hall leads the company in pioneering Federated AI approaches to drug design, aiming to tackle some of the world's most challenging diseases through collaborative data-driven methodologies.
About Qubigen
Qubigen's Federated AI system enables high-powered, innovative drug design that keeps your data private, whether you're working alone or collaborating with global partners. Revolutionary molecular generation and virtual screening processes, powered by quantum chemistry, help deliver best-in-class, fully optimized drug candidates to de-risk development and enhance your portfolio.
Seeking Collaborators, Clients and Partnerships
Qubigen is actively seeking collaborators, clients, and partnerships with organizations interested in leveraging Federated AI for drug design. Qubigen’s technology can help identify lead candidates faster, potentially shaving years off of traditional medicinal chemistry approaches.
Qubigen can provide value to your project in three use-cases:
'Active data' - Hit-to-lead programs: For targets with early hits (e.g., binding or inhibition data), our secure AI platform and virtual screening can streamline development, reducing costs and timelines.
'Low data' - Dormant datasets: We can revitalize incomplete datasets using our in-house database and Federated AI to uncover new opportunities. This enables the development novel medicines, particularly in areas where data privacy and security are paramount.
'No data' - Hit identification: For targets without initial hits, our AI-driven quantum chemistry virtual screening and optimization pipeline can propose and refine compounds with promising properties.
If any of these cases would be valuable to you, book an initial demonstration with us, to show you that it works: www.qubigen.com/contact
About Bio 25
The Bio25 International Convention is taking place from June 16–19 at the Boston Convention & Exhibition Center and gathers over 20,000 biotech leaders from around the globe to discuss the future of biotechnology. Bio25 is "the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech".
Join Us in Boston
If you're attending BIO 2025 and are interested in exploring partnership opportunities with Qubigen, we encourage you to attend Dr. Hall's presentation. If you are interested in discussing potential collaborations, private projects, or partnerships, we'd love to meet with you. Please reach out to us to schedule a meeting during the convention. Qubigen will be using the BIO Partnering™ platform, enabling both our team and potential partners to easily schedule one-on-one meetings with each other.
Don’t hesitate, however, to reach out to us directly:
For more information see our previous blog post on Bio 2025
We look forward to connecting with you in Boston and exploring how we can work together.
Qubigen - Accelerate Drug Design Without Exposing Secrets.
Whether you're advancing active programs, reviving dormant data, or starting from scratch, Qubigen’s secure AI platform and virtual screening capabilities can help you identify, optimize, and accelerate the path to novel drug candidates. Get in touch to explore how we can support your next discovery.
